title: Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.
abstract: OBJECTIVE
  To investigate clinical efficacy of pioglitazone in association with plasma adiponectin concentration in type 2 diabetic patients.
  
  
  METHODS
  Ten diabetic patients were treated with 15 or 30 mg of pioglitazone for 8 weeks, and association between plasma adiponectin concentration before treatment and decrease in glycated albumin levels was examined.
  
  
  RESULTS
  Treatment with pioglitazone for 8 weeks lowered glycated albumin level (27.1 +/- 1.2 to 23.8 +/- 1.4%, p < 0.05), and inverse relationship between changes in glycated albumin and plasma adiponectin concentration before treatment was revealed (r = -0.66, p < 0.05). Plasma adiponectin concentrations of patients whose glycated albumin level reduced by more than 10% of the levels before treatment were significantly lower than those of patients whose glycaemic control was affected less (5.2 +/- 0.6 vs. 8.0 +/- 1.0 micro g/ml, p < 0.05).
  
  
  CONCLUSIONS
  Lower plasma adiponectin concentration predicts the clinical efficacy of pioglitazone.
authors.affiliation: Department of Metabolism and Endocrinology, Department of Clinical Research, National Kyushu Medical Centre, Fukuoka, Japan. hiramatsu@med.hosp.go.jp
authors.forename: S
authors.initials: S
authors.lastname: Hiramatsu
authors.forename: Y
authors.initials: Y
authors.lastname: Tajiri
authors.forename: T
authors.initials: T
authors.lastname: Karashima
mesh_terms: D052242:Adiponectin; D000418:Albumins / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D007328:Insulin / Q000008:administration & dosage; D007333:Insulin Resistance / Q000502:physiology; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D011506:Proteins / Q000032:analysis*; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D052242:Adiponectin; D000418:Albumins; D007004:Hypoglycemic Agents; D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; D045162:Thiazolidinediones; D005947:Glucose; D000077205:Pioglitazone